Mini Focus on DiabetesThe Present and FutureJACC State-of-the-Art ReviewThe Changing Landscape of Diabetes Therapy for Cardiovascular Risk Reduction: JACC State-of-the-Art Review
Central Illustration
Key Words
Abbreviations and Acronyms
Cited by (0)
Drs. Newman and Berger have been partially funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health (K23HL125991 to Dr. Newman; HL114978 to Dr. Berger). Dr. Aleman has been partially funded by the American Heart Association. Funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the paper. Dr. Weintraub has received honoraria from Amgen, Sanofi, and Gilead for consulting; has served on the Speakers Bureau for Amgen; and has received research funding from Amarin, Sanofi, Akcea, and Ionis. Dr. Berger has received research funding from AstraZeneca and Janssen. Dr. Schwartzbard has received research funding to New York University from Merck/Pfizer, Amarin, Sanofi, and Ionis; and has served as a consultant to the formulary committee for Optum Rx. Dr. Vani has reported that he has no relationships relevant to the contents of this paper to disclose.